Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTVMO5W)

DTT Name	Interleukin-25 (IL25)
Synonyms	UNQ3120/PRO10272; Interleukin-17E; IL17E; IL-25; IL-17E
Gene Name	IL25
DTT Type	Clinical trial target	[1]
BioChemical Class	Cytokine: interleukin
UniProt ID	IL25_HUMAN
TTD ID	T62241
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MRERPRLGEDSSLISLFLQVVAFLAMVMGTHTYSHWPSCCPSKGQDTSEELLRWSTVPVP PLEPARPNRHPESCRASEDGPLNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQT GSHMDPRGNSELLYHNQTVFYRRPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG
Function	Proinflammatory cytokine favoring Th2-type immune responses. Induces activation of NF-kappa-B and stimulates production of the proinflammatory chemokine IL-8.
KEGG Pathway	Cytokine-cytokine receptor interaction (hsa04060 ) Inflammatory bowel disease (IBD) (hsa05321 ) Rheumatoid arthritis (hsa05323 )
Reactome Pathway	Interleukin-17 signaling (R-HSA-448424 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[1]
------------------------------------------------------------------------------------

References

1	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.